Challenges, Future Directions in Treating Higher-Risk MDS Discussed by Roger Lyons, MD, FACP

By Cecilia Brown, Roger Lyons, MD, FACP - Last Updated: December 13, 2022

Roger Lyons, MD, FACP, discusses challenges and future directions in treating patients with higher-risk myelodysplastic syndromes. Dr. Lyons and colleagues presented a real-world retrospective observational study on treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting during the 2022 American Society of Hematology Annual Meeting.

Post Tags:MDS ASH 22
Editorial Board